CeriBell Valuation Multiples

CeriBell Overview

About CeriBell

CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.

Founded

2014

HQ

Employees

327

Website

ceribell.com

Sectors

Medical DevicesDeepTechHealthTech

Financials (LTM)

Revenue: $96M

EBITDA: ($52M)

EV

$660M

Valuation Multiples

Multiples.vc

Start free trial

CeriBell Financials

CeriBell reported last 12-month revenue of $96M and negative EBITDA of ($52M).

In the same LTM period, CeriBell generated $84M in gross profit, ($52M) in EBITDA losses, and had net loss of ($54M).

CeriBell P&L

In the most recent fiscal year, CeriBell reported revenue of $89M and EBITDA of ($50M).

CeriBell expects next 12-month revenue of XXX and NTM EBITDA of XXX

CeriBell Stock Performance

CeriBell has current market cap of $797M, and enterprise value of $660M.

CeriBell's stock price is $21.18.

CeriBell Valuation Multiples

CeriBell trades at 6.9x EV/Revenue multiple, and (12.7x) EV/EBITDA.

CeriBell Financial Valuation Multiples

As of April 20, 2026, CeriBell has market cap of $797M and EV of $660M.

Equity research analysts estimate CeriBell's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

CeriBell has a P/E ratio of (14.8x).

CeriBell Margins & Growth Rates

CeriBell's revenue in the last 12 month grew by 27%.

CeriBell's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.

CeriBell's rule of 40 is (20%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

CeriBell's rule of X is 20% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

CeriBell Public Comps

See public comps and valuation multiples for other Medical Devices comps.

CeriBell M&A Activity

CeriBell acquired XXX companies to date.

Last acquisition by CeriBell was on XXXXXXXX, XXXXX. CeriBell acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

CeriBell Investment Activity

CeriBell invested in XXX companies to date.

CeriBell made its latest investment on XXXXXXXX, XXXXX. CeriBell invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).